Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518813 | 0.72 | JAK2 (0.49) | BRD4BRD2CREBBPJAK2NR3C1 | |
| SCHEMBL16109961 | 0.69 | BRD4 (0.52) | BRD4CREBBPJAK2 | |
| SCHEMBL17698652 | 0.69 | BRD4 (0.45) | BRD4BRD2CREBBP | |
| SCHEMBL17698649 | 0.69 | BRD4 (0.48) | BRD4BRD2CREBBP | |
| SCHEMBL17802065 | 0.68 | BRD4 (0.49) | BRD4BRD2CREBBP | |
| SCHEMBL16110592 | 0.68 | BRD4 (0.50) | BRD4BRD2CREBBP | |
| SCHEMBL17698728 | 0.66 | BRD4 (0.55) | BRD4BRD2CREBBPJAK2 | |
| SCHEMBL18635479 | 0.66 | BRD4 (0.43) | BRD4BRD2CREBBP | |
| SCHEMBL17698710 | 0.65 | BRD4 (0.47) | BRD4BRD2JAK2 | |
| SCHEMBL17698716 | 0.65 | BRD4 (0.52) | BRD4CREBBPJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | claimed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | claimed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | claimed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | claimed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | claimed |
| EP-3010918-A2 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2016-04-27 | — | — | EP | claimed |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885BRD2 3/4885CREBBP 23/4885 |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885BRD2 3/4885CREBBP 21/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885BRD2 3/4885CREBBP 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.